Martin Tolar

3PUBLICATIONS
0CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Mar 13, 2024
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.

Martin Tolar, John A Hey, Aidan Power

|Jul 02, 2021
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.

Martin Tolar, John Hey, Aidan Power

|Aug 14, 2020
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.

Martin Tolar, Susan Abushakra, John A Hey

Pageof 1

Frequent Collaborators